Description
Right2Try Inc.™ is a company that upholds the rights of patients with terminal diagnoses to choose alternative treatment options under the Right to Try Act of 2017.
HydroxyMed is defined as a chemical formulation comprising hydroxychloroquine to:
1) Target malignant cells in the following ways:
a) by inhibition of multidrug resistance
b) by improving chemotherapy cell penetration
c) by potentiation of presentation of major histocompatibility complexes
d) by intercalation directly into DNA
2) To temper severe systemic inflammatory responses to filoviruses both through dysregulation of lysosomes and lysosomal pH and through decreased production of tumor necrosis factor alpha and interferons.
3) To prevent Toll-like receptor activation by binding directly to nucleic acids in the activation pathway and thus lowering the body’s primary cell-mediated inflammatory response.
